Charles River Laboratories Intl. Inc vs Viking Holdings Ltd Ordinary Shares — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Viking Holdings Ltd Ordinary Shares trades at $81.62 (market cap $36.46B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 2.6× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Viking Holdings Ltd Ordinary Shares for 0 Days on average.
| CRL | VIK | |
|---|---|---|
Market Cap | $14.23B | $36.46B |
Volume | 1,176,885 | 3,461,906 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $108.26 |
52-Week Low | $149.93 | $57.08 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $17.06B | $38.84B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →